GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi as shareholders, has announced that the Committee for Medicinal Products for Human Use, CHMP, of the Europe Medicines Agency, EMA, has issued a positive opinion recommending marketing authorisation for Vocabria in combination with Johnson & Johnson Innovative Medicine’s (JNJ) Rekambys for the treatment of HIV-1 infection in adolescents 12 years of age and older and weighing at least 35 kg who are virologically suppressed.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK announces EMA granted PRIME Designation for GSK5764227
- GSK announces CHMP of the EMA recommended expanding approval of Jemperli
- GSK announces FDA granted BTD for Jemperli
- Relation announces two strategic collaborations with GSK
- GSK says median overall survival not reached in multiple myeloma study